文献速递神经免疫

奥瑞珠单抗皮下制剂治疗多发性硬化:III期OCARINA II研究结果

Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study.
PubMed 文献 · Neurology · 2025-04-17

OCARINA II是一项III期随机开放标签研究,纳入118例RMS/PPMS患者,比较奥瑞珠单抗皮下920 mg与静脉600 mg的药代动力学。结果显示皮下给药在AUCW1-12和AUCW1-24均非劣于静脉给药,疗效与安全性相当,支持皮下给药作为新选择。

要点

  • 皮下奥瑞珠单抗920 mg在药物暴露方面非劣于静脉600 mg。
  • 第48周时两组MRI活动均接近完全抑制,复发罕见。
  • 注射反应发生率51.5%,均为轻中度,随注射次数减轻。

核心结论

  • 皮下奥瑞珠单抗920 mg在药物暴露方面非劣于静脉600 mg,疗效与安全性相当,为多发性硬化患者提供额外治疗选择。

研究设计与样本

  • III期随机开放标签研究,纳入118例未接受过奥瑞珠单抗的RMS/PPMS患者,年龄18-65岁,EDSS评分0-6.5。

主要发现

  • 主要终点AUCW1-12的几何均值比(90% CI)为1.29(1.23-1.35),AUCW1-24为1.27(1.21-1.34),均显示皮下非劣于静脉。
  • 第48周时,OCR IV/SC组111/118例、OCR SC/SC组114/118例已接受皮下给药。
  • MRI活动接近完全抑制:OCR IV/SC组0/113例、OCR SC/SC组0/113例有T1病灶;分别1/114例和1/113例有新发/扩大T2病灶。
  • 复发:OCR IV/SC组2例(1.9%)各1次复发,OCR SC/SC组2例(1.9%)各1次复发,另1例(0.9%)2次复发。
  • 两组均观察到快速持续B细胞耗竭,血清神经丝轻链降低程度相当。

关键数值与推荐

  • 皮下奥瑞珠单抗920 mg每24周一次,静脉奥瑞珠单抗600 mg(分两次300 mg,间隔2周)。
  • 至少接受一剂皮下920 mg的患者中,OCR IV/SC组和OCR SC/SC组不良事件发生率分别为75.4%和86.4%,严重不良事件分别为5.9%和2.5%。
  • 最常见的不良事件为注射反应(51.5%),局部和全身注射反应分别见于117/233例(50.2%)和27/233例(11.6%),均为轻中度。

临床怎么用

  • 皮下奥瑞珠单抗920 mg可作为多发性硬化患者的治疗选择,药物暴露非劣于静脉给药,疗效与安全性相当。

局限性

  • 原文未述局限性

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND AND OBJECTIVES: IV-administered ocrelizumab (OCR) is approved for the treatment of relapsing and primary progressive multiple sclerosis (RMS/PPMS). OCARINA II (NCT05232825) was designed to demonstrate noninferiority in drug exposure of OCR subcutaneous (SC) vs IV administration. METHODS: This phase 3, randomized, open-label study enrolled OCR-naive patients aged 18-65 years with RMS/PPMS and an Expanded Disability Status Scale score of 0-6.5. Patients received OCR IV 600 mg or OCR SC 920 mg (controlled period), followed by OCR SC 920 mg every 24 weeks, up to week 96 (OCR IV/SC and OCR SC/SC). The primary end point was OCR area under the serum concentration-time curve from day 1 to week 12 (AUCW1‒12); other end points included clinical, biomarker, and pharmacodynamic outcomes and safety data. RESULTS: Baseline demographics were balanced across OCR IV/SC and OCR SC/SC arms (N = 118/118, 40.0 ± 11.9/39.9 ± 11.4 years, 59.3%/65.3% female, 89.0%/89.0% with RMS). The study demonstrated noninferiority of OCR SC 920 mg to OCR IV 600 mg for the primary end point AUCW1-12 and also over the dosing interval for AUCW1‒24 (geometric mean ratios [90% CI] 1.29 [1.23-1.35] and 1.27 [1.21-1.34], respectively). At week 48, 111 of 118 (OCR IV/SC) and 114 of 118 (OCR SC/SC) had received OCR SC. A near-complete suppression of MRI activity was reported in OCR IV/SC and OCR SC/SC: 0 of 113 and 0 of 113 patients had T1 lesions while 1 of 114 and 1 of 113 had 2 and 1 new/enlarging T2 lesions, respectively. Two patients (1.9%) in each arm had 1 relapse, and 1 patient (0.9%; OCR SC/SC) had 2 relapses. In both arms, rapid and sustained B-cell depletion was observed and serum neurofilament light chain reduction was comparable. Patients receiving at least 1 dose of OCR SC 920 mg in the OCR IV/SC and OCR SC/SC arms reported adverse events (AEs): 75.4% and 86.4%, and serious AEs: 5.9% and 2.5%. The most frequently reported AEs were injection reactions (IRs, 51.5%); local and systemic IRs were experienced by 117 of 233 patients (50.2%) and 27 of 233 patients (11.6%), respectively. All IRs were mild/moderate; intensity and duration decreased with subsequent injections. DISCUSSION: The OCR SC formulation demonstrated noninferiority to OCR IV formulation regarding drug exposure, providing comparable efficacy and safety and an additional treatment option for patients with multiple sclerosis. CLASSIFICATION OF EVIDENCE: This study provides Class II evidence that a single SC injection of 920 mg of OCR achieves a noninferior 12-week area under serum concentration-time curve to that of 2 IV infusions of 300-mg OCR administered 2 weeks apart. TRIAL REGISTRATION INFORMATION: ClinicalTrials.gov Identifier NCT05232825; submitted: January 27, 2022; first patient enrolled: May 3, 2022; available at: clinicaltrials.gov/study/NCT05232825?term=NCT05232825&rank=1.

来源:Neurology,查看原文。版权归原作者所有。

引用

  1. Newsome SD, Krzystanek E, Selmaj KW, et al. Subcutaneous Ocrelizumab in Patients With Multiple Sclerosis: Results of the Phase 3 OCARINA II Study. Neurology. 2025. PMID: 40245351. doi:10.1212/WNL.0000000000213574

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。